Arbutus Biopharma Corp operates within the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Arbutus Biopharma Corp with three other
companies in this sector in CANADA :
Liminal BioSciences Inc
sales of 4.90 million Canadian Dollars [US$3.68 million]
of which 97%
was Plasma derived therapeutics),
Antibe Therapeutics Inc
(9.54 million Canadian Dollars [US$7.15 million]
Pond Technologies Holdings Inc
(6.14 million Canadian Dollars [US$4.60 million]
of which 58%
was Nutraceutical Products).
During the year ended December of 2019, sales at
Arbutus Biopharma Corp were C$7.95 million (US$5.96 million).
increase of 3.0%
versus 2018, when the company's sales were C$7.73 million.
Despite this increase, sales are still
below the level achieved in 2017, when Arbutus Biopharma Corp
reported sales of C$13.86 million.